About Contact Us Careers
Sign In

Botulinum Toxin Market Size & Share, by Toxin Type (A, B); Application (Medical, Aesthetic); Gender (Female, Male); Age Group (13-19, 20-29, 30-39, 40-54, 55, Above); End-user (Hospitals, Dermatology Clinics, Spas, Cosmetic Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4546
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Companies Dominating the Botulinum Toxin Landscape

top-features-companies
    • Merz Pharma GmbH & Co. KGaA
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • USWM, LLC
    • Medytox Inc.
    • Hugel, Inc.
    • Ipsen Group
    • Revance Therapeutics, Inc.
    • AbbVie Inc.
    • Galderma S.A.
Browse Key Market Insights with Data Illustration:

In the News

  • Allergan, an AbbVie Inc. announced the U.S Food and Drug Administration (FDA) approval to expand the label of botox to include eight more muscles to treat adults with upper limb spasticity. The new approval was significant as it treated disabling neurological conditions influencing the quality of life of a patient.

  • Ipsen Group declared that Dysport, a clostridium botulinum type A toxin-haemagglutinin complex received the U.S. FDA. Dysport is the first UK botulinum toxin to get approved for pediatric spasticity therapy in upper and lower limbs.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4546
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising disposable income and the growing prevalence of neurological disorders are the major factors driving the growth of the botulinum toxin market.

The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2023 – 2033.

Associated side effects with the botulinum toxin procedures, and high cost of botulinum toxin methods are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Merz Pharma GmbH & Co. KgaA, USWM LLC, Revance Therapeutics, Inc., Ipsen Group, Medytox, Inc., Hugel, Inc., AbbVie Inc., Galderma S.A., Evolus, Inc. and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, gender, age group, end-user, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying